.svg)
Our next-generation in vivo immunotherapy
Stimulated-Ghost-Cells innovation
Data-driven selection
Selection of well-characterized allogeneic human cell lines that reflect the heterogeneity of the targeted indication and represent patient diversity — including key mutations and different phenotypic profiles.
Mimicking stress conditions of relapsing patients
Stimulation by standards of care and physical stressors to reveal over 200 cancer-related proteins.These proteins represent tumor specificity, plasticity, and resistance mechanisms, validated through proteogenomic and predictive modeling.
Immune “flare” + ghost cell inactivation
In vitro haptenation flags non-visible cancer-related anitgens to boost their recognition in vivo, by innate immune system. Final inactivation in ghost cells supporting haptenatedproteins and ensuring a safe in vivo education of the immune system.
Hapten
Dinitrofluorobenzene (DNFB)
Carrier
Cancer Related Proteins (CRP)
Data-driven selection
Selection of well-characterized allogeneic human cell lines that reflect the heterogeneity of the targeted indication and represent patient diversity — including key mutations and different phenotypic profiles.
Mimicking stress conditions of relapsing patients
Stimulation by standards of care and physical stressors to reveal over 200 cancer-related proteins.These proteins represent tumor specificity, plasticity, and resistance mechanisms, validated through proteogenomic and predictive modeling.
Immune “flare” + ghost cell inactivation
In vitro haptenation flags non-visible cancer-related anitgens to boost their recognition in vivo, by innate immune system. Final inactivation in ghost cells supporting haptenatedproteins and ensuring a safe in vivo education of the immune system.
Hapten
Dinitrofluorobenzene (DNFB)
Carrier
Cancer Related Proteins (CRP)
We initiate a multi-specific in vivo immune response against tumor
Our products are developed using our ready-to-use therapeutic platform, designed to generate first-in-class immunotherapies
Reproducing in vivo tumor heterogeneity
> Using Standards of Care and physical shock of the selected indication
> Precision medicine applied to large patient populations
Neoantigens and cancer proteins validation
> Proteogenomic profiling matched with biopsies datasets
> Data science & deep learning prediction tools
Advanced antigens presentation methods
> Fonctionnal validation by immunoassays
Standardized & Scalable manufacturing process
> GMP ready & specifically replicable to other solid tumors
> Platform & Product worldwide patented
Anticipating tumor evolution from 1st line to overcome current limitations
.png)
BreAK CRC 001 Study Design NCT06934538
Open label, multicenter, dose-escalation and cohort-expansion phase I/IIA trial of STC-1010 in patients with unresectable locally advanced or metastatic colorectal cancer (CRC) in first line setting
Our awards
.png)
GOLDEN TICKET PFIZER x BIOLABS
SEAL OF EXCELLENCE
MOST PROMISING PROJECT
BEST BIOTECH
CANCER STREAM GRADUATION
BIG STARTUP LYON ST-ETIENNE
AWARD
BEST PHARMA STARTUP NOMINATION
